Merck & Co., Inc. (MRK)
NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
| Previous close | 131.20 |
| Open | 131.72 |
| Bid | 129.50 x 900 |
| Ask | 0.00 x 900 |
| Day's range | 129.33 - 132.20 |
| 52-week range | 99.14 - 133.10 |
| Volume | |
| Avg. volume | 8,403,666 |
| Market cap | 329.598B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | 144.58 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.08 (2.37%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
- Business Wire
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
RAHWAY, N.J., April 29, 2024--Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
- Business Wire
Merck Announces First-Quarter 2024 Financial Results
RAHWAY, N.J., April 25, 2024--Merck Announces First-Quarter 2024 Financial Results
- Business Wire
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
RAHWAY, N.J., April 04, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA for the first-line treatment of certain patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor KRAS G12C mutations and express PD-L1 (tumor proportion score [TPS] ≥50%).
© 2024 Yahoo. All rights reserved.